Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

Tazemetostat blocks any activity of the EZH2 methyltransferase, which may help keep the cancer cells from further growth.

Pharmacies are using technology not only to offer safe filling, but generate greater engagement with their customer base.

Pfizer will become the first to launch 3 oncology monoclonal antibody biosimilar treatments to the US market.

The study was the first to examine proton pump inhibitors use in breast cancer survivors.

Top news of the day from across the health care landscape.

A proposed FDA guidance could significantly impact veterinary practices and their ability to compound medicines for animal patients, according to a national survey.1

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend.

Valoctocogene roxaparvovec (Valrox, BioMarin Pharmaceutical Inc) would be the first gene therapy in the United States for the most common form of hemophilia if approved by the FDA.1

The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.

Top news of the day from across the health care landscape.

Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.

Top news of the day from across the health care landscape.

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.

The report projects changes in upcoming health care markets, including kidney care, digital health, drug cost transparency, the loneliness epidemic, and the self-care market.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Safety net providers, which historically work in underserved communities, have successfully petitioned state legislatures to take action on 340B 2-tier pricing.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.

Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Tofacitinib, currently used to treat rheumatoid arthritis and ulcerative colitis, has a correcting effect on defects that occur in inflammation.

Top news of the day from across the health care landscape.

Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.

Top news of the day from across the health care landscape.

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.